Intellia Therapeutics Shares Rise on Positive Lonvo-Z Trial Results
Intellia Therapeutics (NASDAQ:NTLA) shares surged by 23.20% after the company reported encouraging Phase 3 results for its gene-editing treatment candidate, Lonvo-Z, which showed an 87% reduction in HAE attacks compared to a placebo group.
Tickers: $NTLA
Topics: Biotech CRISPR Gene Editing Hereditary Angioedema (HAE) Phase 3 Trials